Artemisinin and Derivatives Cancer Studies by Year

Cancer Types

| ▪ Breast                  | ▪ Melanoma                  |
| ▪ Cervical               | ▪ Multiple Myeloma          |
| ▪ CNS                    | ▪ Oral                      |
| ▪ Colorectal             | ▪ Ovarian                   |
| ▪ Head & Neck            | ▪ Pancreatic                |
| ▪ Leukemia/Lymphoma      | ▪ Pituitary                 |
| ▪ Liver                  | ▪ Prostate                  |
| ▪ Lung                   | ▪ Sarcomas                  |

2012


(18) Cabello CM et al. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. *Invest New Drugs.* 2011 May 6


(42) Zhao Y et al. Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. *Int Immunopharmacol.* 2011 Dec;11(12):2039-46


(56) Liu WM et al. The anti-malarial agent artesunate possesses anti-cancer properties that can be enhanced by combination strategies. *Int J Cancer.* 2010 Sep 30.


(99) Rosenthal AS et al. Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. *J Med Chem*. 2009 Feb 26;52(4):1198-203.


---

**2007 (23)**


---

2006 (17)


2005 (12)


---

2004 (15)


---

2003 (9)


---

**2001 (6)**


---

**2000 (1)**

Before 2000 (14)

(237) Beekman AC et al. Cytotoxicity of artemisinin, a dimer of dihydroartemisinin, artemisitene and aupatoriopicrin as evaluated by the MTT and clonogenic assay. Phytother Res. 1998 Dec;10(2):140-144.


